A combination gene therapy strategy using an AS Psi-gag antisense RNA (targeted against the packaging signal and the gag-coding region) and a multimeric hammerhead ribozyme Rz 1-9 (targeted against nine sites within the env-coding region) or Rz 1-14 (targeted against 14 sites within the 5' leader and the pro-, pol-, vif-and envcoding regions) was assessed for inhibiting HIV-1 replication. A murine stem cell virus (MSCV)-based MGIN vector was used to express Rz 1-9 , Rz
ABSTRACT
A combination gene therapy strategy using an AS Psi-gag antisense RNA (targeted against the packaging signal and the gag-coding region) and a multimeric hammerhead ribozyme Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] (targeted against nine sites within the env-coding region) or Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (targeted against 14 sites within the 5' leader and the pro-, pol-, vif-and envcoding regions) was assessed for inhibiting HIV-1 replication. A murine stem cell virus (MSCV)-based MGIN vector was used to express Rz 1-9 , Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , AS Psi-gag , Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] AS Psi-gag , or Rz 1-14 AS Psi-gag RNA in a CD4+ T lymphoid cell line. Stable transductants were shown to express similar levels of interfering RNA. HIV-1 replication was inhibited in cells expressing Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Little inhibition of HIV-1 replication was observed in cells expressing AS Psi-gag RNA. Thus, the multimeric hammerhead ribozymes inhibit HIV-1 replication better than the antisense RNA. Inhibition of HIV-1 replication in cells expressing Rz 1-9 AS Psi-gag or Rz 1-14 AS Psi-gag RNA was worse than that obtained with the multimeric ribozymes alone. This result suggests that co-expression of antisense RNA decreases the anti-HIV potential of ribozymes. The multimeric ribozymes and the antisense RNA were designed to target different sites within the HIV-1 RNA. They are not expected to interact with each other. Neither are they expected to compete with each other for binding to the HIV-1 RNA. Instead, the antisense RNA binding to its (1553 nt-long) target site may have resulted in a decreased ribozyme turn over. Furthermore, since the antisense RNA/HIV-1 RNA hybrids are degraded by the cells, the co-expressed antisense RNA may have led to ribozyme degradation.
INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) is caused by a lentivirus, human immunodeficiency virus type-1 (HIV-1), which infects the CD4+ T lymphocytes and monocytes/macrophages. Drug and gene therapy strategies are being developed to inhibit HIV-1 replication. The anti-HIV genes have been designed to express interfering RNAs or proteins (1) (2) (3) (4) (5) . Of all the anti-HIV-1 genes tested to date in our laboratory, the multimeric hammerhead ribozymes rank at the top (6-8), followed by the antisense RNAs (9-11).
Antisense RNAs can be designed to prevent nuclear export, translation, and packaging of HIV-1 RNA as well as to inhibit progeny virus replication (3). Ribozymes are small catalytic RNAs that can be designed to specifically recognize and cleave the HIV-1 RNA in the nucleus, cytoplasm, and the progeny viruses such that either no virus is produced or the viruses produced are noninfectious (3).
The Moloney murine leukemia virus (MoMuLV)-based MoTN vector (12) was previously used to express two antisense RNAs. The AS Psi-gag RNA targeted against the packaging signal (Psi) and the gag-coding region of HIV-1 RNA (9) and the AS LTR-GE RNA targeted against the U3RU5 region and the gag-and env-coding regions of HIV-1 RNA (10). Both of these antisense RNAs were shown to confer excellent inhibition of HIV-1 replication for the 30-80 days for which they were tested (9,10). These antisense RNAs were also found to be packaged by the progeny viruses, which were further shown to have a markedly reduced infectivity (10) . The antisense RNAs are very likely to have been copackaged with the HIV-1 RNA.
The MoMuLV-based MoTN vector (12) was previously modified in our laboratory to develop the MoTiN vector (13) . This vector was designed to allow anti-HIV gene expression in a constitutive manner with further upregulation in the HIV-infected cells. It was used to express a number of monomeric hammerhead ribozymes targeted against various sites within the HIV-1 RNA (14, 15) . These ribozymes conferred varying degree of protection to a human CD4+ T lymphoid (MT4) cell line (14, 15) . However, none of them conferred complete protection, despite active ribozyme production and target site conservation (15) . This vector was then used to express a multimeric hammerhead ribozyme (Rz 1-9 ) targeted against nine sites that are highly conserved within the env-coding region of HIV-1 RNA (clade B; 6,7). MoTiN-Rz 1-9 conferred excellent protection for the 60 days for which it was tested (7). The mouse stem cell virus (MSCV)-based MGIN vector (16) was then used to express Rz 1-9 , Rz 10-14 , (expressing five ribozymes that are targeted against the 5' leader region and the pro-, pol-, and vifcoding regions conserved in all major clades of HIV-1), and Rz 1-14 (containing Rz 1-9 and Rz 10-14 ) (8). Rz 1-14 was found to be even better than Rz 1-9 in inhibiting virus replication (8) .
The MoTN-AS Psi-gag (9, 11) and the MoTiN-Rz 1-9 (7) vectors were also shown to confer protection to the transduced peripheral blood T lymphocytes upon challenge with the clinical isolates of HIV-1 (10, 17) .
In this paper, we have assessed whether the antisense RNA and the multimeric hammerhead ribozymes can be co-expressed to develop a combination gene therapy strategy. The MGIN vector (16) was used in this study to express the genes encoding the multimeric hammerhead ribozymes (Rz 1-9 and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , the antisense RNA (AS Psi-gag ), or both the antisense RNA and the multimeric ribozymes (Rz 1-9 AS Psi-gag and Rz 1-14 AS Psi-gag ).
MATERIALS AND METHODS

Construction of retroviral vectors
Genes encoding the multimeric hammerhead ribozymes and/or the antisense RNA were cloned in the MGIN vector (16) between the enhanced green fluorescence protein (egfp) gene and the internal ribosome entry site (IRES). Before proceeding with vector constructions, unique Csp 451 and Bgl II sites were introduced 3' to the egfp gene, as described previously (8) . Briefly, a 5' primer (containing the Eco RI site) and a 3' primer (containing the Csp 451, Bgl II, and Not I sites) were used to PCR amplify the egfp gene. The PCR product was digested with the Eco RI and Not I enzymes and cloned at the corresponding sites within the MGIN vector. The modified MGIN vector was used in the subsequent cloning experiments.
The MGIN-Rz 1-9 and MGIN-Rz 1-14 vectors were constructed as described previously (8) . For MGIN-AS Psigag vector construction, the 1553 nt-long AS Psi-gag sequences were amplified by PCR using the pNL4-3 (18) template DNA and the AS-F primer (5'-GTT-CGA-AAG-ATC-TGC-GGC-CGC-GGC-CGG-ATC-TTC-CCT-AAA-AAA-TTA-GCC-3'; containing the Not I site) and the AS-R primer (5'-GTG-ATC-AGG-GCC-CAA-GTA-GTG-TGT-GCC-CGT-CTG-3'), as described previously (8) . Klenow (Amersham Pharmacia Biotech Inc., Quebec, Canada) was used to repair the ends of the PCR product, as described earlier (19) . The 1591 bp product was then used in a blunt-end ligation into the MGIN vector at the Bgl II site, which was filled using Klenow. Orientation of AS Psi-gag gene in the MGIN-AS Psi-gag vector was confirmed by PCR and restriction enzyme analyses.
The MGIN-Rz 1-9 AS Psi-gag and MGIN-Rz 1-14 AS Psigag vectors were constructed as follows. The Not I fragment (containing the AS Psi-gag gene) of MGIN-AS Psi-gag was cloned at the same site downstream of the Rz 1-9 and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] genes in the MGIN-Rz 1-9 and MGIN-Rz 1-14 vectors. The correct clones, containing the MGIN-Rz 1-9 AS Psi-gag and MGIN-Rz 1-14 AS Psi-gag vectors, were screened by PCR and restriction enzyme analyses.
Transduction and selection of stable MT4 transductants
Amphotropic MGIN, MGIN-Rz 1-9 , MGIN-Rz 1-14 , MGIN-AS Psi-gag , MGIN-Rz 1-9 AS Psi-gag , and MGIN-Rz 1- (22) . The pools of G418 R stable MT4 transductants were selected and then used in the subsequent experiments.
PCR analysis of genomic DNA from MT4 transductants
Genomic DNA was extracted from the stable MT4 transductants that either lacked (control) or expressed Rz 1-9 , Rz 1-14 , AS Psi-gag , Rz 1-9 AS Psi-gag , or Rz 1-14 AS Psi-gag (23) . PCRs were performed, as described previously (8, 15) , using the MGIN-5' primer (5'-CTC-TCG-GCA-TGG-ACG-AG-3') and the MGIN-3' primer (5'-ATG-CTG-GTC-AAG-AAG-AC-3'), which bind to the vector sequences upstream and downstream of the Rz 1-9 , Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and AS Psi-gag genes. The Gap-5' primer (5'-TCT-ACT-GGC-GCT-GCC-AAG-3') and the Gap-3' primer (5'-TCT-AGA-CGG-CAG-GTC-AGG-3') were used to amplify a 122 bp region within the cellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. The PCR products were analyzed by electrophoresis on a 1 or 1.5% agarose gel, as indicated.
RT-PCR analysis of total RNA from MT4 transductants
Total RNA was extracted from the stable MT4 transductants (24) and treated with the RQI RNase-free DNase (Promega Corp.; Madison, WI), as described previously (8) . The RNA samples were analyzed by PCR using the Gap-5'/Gap-3' primer pair to ensure that they are free of DNA contamination. The RNA samples were then analyzed by the semi-quantitative RT-PCR, as described previously (8, 25) . Reverse transcriptions were performed using the Neo-3' primer (5'-CTC-TTC-GTC-CAG-ATC-ATC-3') or the Gap-3' primer, followed by PCR using the Neo-5' primer (5'-CAA-GAC-CGA-CCT-GTC-CGG-3') and the 32 P-labelled Neo-3' primer or the Gap-5' primer and the 32 P-labelled Gap-3' primer; the 3' primers were 5'-end labeled (~1.3 x 10 9 cpm/mg) using [gamma 32 P] ATP (Amersham Canada Ltd.; Oakville, Canada; 6000 Ci/mmol), as described previously (19) . PCRs were performed for 25 cycles using a higher concentration (5 mg/l) of the 5' and the 32 P-labeled 3' primers, as described previously (8) . As a control, the Neo-5' primer and the 32 Plabeled Neo-3' primer were used to PCR amplify 100 to 100,000 copies of MGIN vector DNA and the Gap-5' primer and the 32 P-labeled Gap-3' primer were used to PCR amplify 0.1 and 0.5 mg/l of cellular genomic DNA (8, 25) . The RT-PCR and PCR products were analyzed on a 2% agarose gel, followed by autoradiography.
In vitro cleavage activity of multimeric ribozymes amplified from the pools of MT4 transductants
Total cellular RNA extracted from the stable MT4 transductants expressing the Rz 1-9 or Rz 1-14 was RT-PCR amplified to generate a template enabling the T7-promoter-driven transcription of Rz 1-9 and Rz 1-14 . Reverse transcription was performed using the MGIN-3' primer, followed by PCR using the T7-MGIN-5' primer (5'-ATA-TCA-TAT-GTA-ATA-CGA-CTC-ACT-ATA-GGG-CGA-CT-C-TCG-GCA-TGG-ACG-AG-3') and the MGIN-3' primer. The PCR products were then transcribed in vitro using the T7 RNA polymerase (Life Technologies; Burlington, Canada) for 2 h at 37°C, as described previously (8) . The reaction was stopped by digesting the template DNA for 10 min with 5 U of RQI RNasefree DNase, followed by phenol extraction and ethanol precipitation.
A similar strategy was used to generate a 1400 nt-long alpha 32 P-labelled HIV-1 env target RNA, which contains the Rz 1-9 and Rz 1-14 target sites. To this end, the pNL4-3 plasmid was used in a PCR with the T7-Env-5' primer (5'-ATA-TCA-TAT-GTA-ATA-CGA-CTC-ACT-ATA-GGG-CGA-GAA-GGA-GAA-ATA-TCA-GC-3') and the Env-3' primer (5'-TCA-CTT-CTC-CAA-TTG-TCC-3'). The PCR product was then transcribed in vitro using [alpha 32 P] UTP (Amersham Canada Ltd.; Oakville, Canada; 3000 Ci/mmol) and the T7 RNA polymerase for 2 h at 37°C, as described previously (8, 15) . The template DNA was digested for 10 min with 5 U of RQI RNase-free DNase, followed by phenol extraction and ethanol precipitation.
Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] or Rz 1-14 and alpha 32 P-labelled env target RNA were used in a trans cleavage reaction as follows (7, 8) . The RNAs were combined in a reaction mixture containing 10 mM NaCl and 40 mM Tris-Cl, pH 8.0. The mixture was heated to 65°C for 5 min, cooled to 37°C, and the reaction was initiated by adding 20 mM MgCl 2 . After 2 h incubation at 37°C, the reaction was stopped by adding 5 mM EDTA. The alpha 32 P-labelled target RNA and its cleavage products were analyzed by 8 M urea-6% polyacrylamide gel electrophoresis, followed by autoradiography.
HIV-1 susceptibility of MT4 transductants
To produce the HIV-1 NL4-3 challenge virus stock, HIV-1 was harvested by collecting the entire cell culture supernatant every day, and the sample containing the highest virus concentration was aliquoted and used (8) . The titer of this virus (infectious units/ml) was determined using the U373-MAGI-CXCR4 CEM cell line (26) .
The pools of stable MT4 transductants (2 x 10 6 cells) were each inoculated with HIV-1 at a multiplicity of infection (m.o.i.) of 0.5, for 2 h at 37°C, as described previously (9, 22) . Cells were then washed twice with the medium, suspended in the same medium, and cultured at 37 o C. The amount of HIV-1 p24 antigen released in the culture supernatants was then measured at different time intervals by enzyme linked immunosorbent assay using a kit (Abbott; Chicago, IL).
RESULTS
The MSCV-based MGIN vector (16) was used to express the antisense RNA (AS Psi-gag ), the multimeric hammerhead ribozymes (Rz 1-9 and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , or the multimeric hammerhead ribozymes and the antisense RNA (Rz 1-9 AS Psi-gag and Rz 1-14 AS Psi-gag ). Amphotropic vector particles were used to transduce the human CD4+ T lymphoid (MT4) cell line (20, 21) . The stable MT4 transductants were then tested for the presence of vector DNA sequences, level of expression of interfering RNAs, ribozyme activity, and inhibition of HIV-1 replication. The Rz 1-9 AS Psi-gag and Rz 1-14 AS Psi-gag were designed to contain the multimeric ribozymes followed by the antisense RNA to enable ribozyme and antisense RNA hybridization to their target sites in a co-linear fashion (Figure 2 ).
Development of pools of stable MT4 transductants expressing the interfering RNAs
Amphotropic MGIN, MGIN-Rz 1-9 , MGIN-Rz 1-14 , MGIN-AS Psi-gag , MGIN-Rz 1-9 AS Psi-gag , and MGIN-Rz 1-14 AS Psi-gag vector particles were each used to transduce the MT4 cell line (20, 21) . Pools of G418 R stable MT4 transductants were then selected and tested without cloning.
The presence of genes encoding the multimeric ribozymes and/or the antisense RNA was confirmed by PCR analysis of the genomic DNA isolated from untransduced and transduced MT4 cells. The MGIN-5'/MGIN-3' primer pair was used for this purpose. This primer pair was designed against sequences upstream (within the egfp gene) and downstream (within the IRES element) of the sites where the genes encoding the interfering RNAs were cloned. The expected size 217, 626, and 906 bp products were detected in the MGIN, MGINRz 1-9 and MGIN-Rz 1-14 vector-transduced samples ( Figure  3A, lanes 2-4) , and 1617, 2026, and 2306 bp products were detected in the MGIN-AS Psi-gag , MGIN-Rz 1-9 AS Psi-gag , and MGIN-Rz 1-14 AS Psi-gag vector-transduced samples ( Figure  3B, lanes 2-4) . No PCR product was detected in the untransduced sample ( Figure 3A , lane 1; Figure 3B , lane 1). As a control, the Gap-5'/Gap-3' primer pair was used to amplify a region within the cellular GAPDH gene. The expected 122 bp product was detected in all untransduced and transduced samples ( Figure 3C, lanes 1-7) .
Vector RNA expression from the 5' LTR promoter was confirmed by a semi-quantitative RT-PCR analysis of total cellular RNAs extracted from the untransduced and transduced MT4 cells. Under the conditions used, a linear relationship existed between the input RNA concentration and the RT-PCR product intensity ( Figure 4A , lanes 8-11; Figure 4B, lanes 8,9) . The semi-quantitative RT-PCR analysis using the Neo-5' primer and the 32 P-labelled Neo-3' primers resulted in the amplification of a 330 bp product, with a similar intensity for all RNA samples ( Figure 4A, lanes 2-7) . This result suggests that the level of expression of the 5' LTR promoter-driven transcript is similar in all MT4 transductants. No RT-PCR product was detected in the untransduced sample ( Figure 4A, lane 1) . The Gap-5' primer and the 32 P-labelled Gap-3' primers were used as a control. A 122 bp product specific for the cellular GAPDH RNA was detected upon semi-quantitative RT-PCR analysis of total cellular RNA from all untransduced and transduced MT4 samples ( Figure 4B, lanes 1-7) . Direct PCR analysis of RNA samples used in these RT-PCRs did not yield any product, confirming the lack of DNA contamination in these samples (results not shown).
To demonstrate the activity of the multimeric hammerhead ribozymes produced in the transduced MT4 cells, Rz 1-9 and Rz 1-14 were amplified from the cellular RNA by RT-PCR using a T7 promoter-containing 5' primer, such that the RT-PCR product could be transcribed in vitro. Rz 1-9 and Rz 1-14 were then used in a trans cleavage reaction in the presence of an alpha 32 P-labelled 1400 ntlong HIV-1 env target RNA. This RNA contains the target sites for the nine ribozymes that are targeted against the env-coding region. These nine ribozymes are present in both multimeric ribozymes Rz 1-9 and Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Therefore, similar cleavage products were obtained upon cleavage of this target RNA by Rz 1-9 and Rz 1-14 ( Figure 5 ). This result indicates that the multimeric ribozymes, Rz 1-9 and Rz 1-14 , expressed in the transduced MT4 cells are active.
HIV-1 susceptibility of MT4 transductants expressing the interfering RNAs
The pools of stable MT4 transductants lacking or expressing the Rz 1-9 , Rz 1-14 , AS Psi-gag , Rz 1-9 AS Psi-gag , or Rz 1-14 AS Psi-gag RNA were each infected with the HIV-1 strain NL4-3 at an m.o.i. of 0.5. Progeny virus production was measured by determining the amount of HIV-1 p24 antigen present in the infected cell culture supernatants ( Figure 6 ). The progeny virus production on day 6 post-infection is reported since only a few rounds of HIV-1 replication would have taken place by this time.
Cells transduced with the control MGIN vector (sample 1) produced a high amount of virus (6.9 ng p24/ml, Figure 6A ). Compared to this, 96% or 100% inhibition of HIV-1 replication was observed in cells expressing the Rz 1-9 (sample 2) or Rz 1-14 (sample 3), whereas only 66% inhibition of HIV-1 replication was observed in cells expressing the AS Psi-gag RNA (sample 4). However, 76% or 96% inhibition of HIV-1 replication was obtained in cells expressing the Rz 1-9 AS Psi-gag (sample 5) or Rz 1-14 AS Psi-gag (sample 6). Similar results were obtained in two independent experiments ( Figure 6A,B) . As a negative control, cells expressing a multimeric hammerhead ribozyme that is not targeted against HIV-1 RNA were infected by HIV-1. No inhibition of virus replication was observed in these cells.
DISCUSSION
The MSCV-based MGIN vector was used to express multimeric hammerhead ribozymes, an antisense RNA, or the multimeric hammerhead ribozymes and the antisense RNA. The Rz 1-9 is targeted against nine highly conserved sites within the env-coding region. It should therefore cleave the unspliced and singly spliced HIV-1 RNAs. 5, 6 Rz 1-14 is targeted against fourteen sites that are highly conserved within the 5' leader region and the pro-, pol-, vif-, and env-coding regions, and should therefore cleave the unspliced and singly spliced HIV-1 RNAs. One of the ribozymes in Rz 1-14 is targeted against the HIV-1 5' leader sequence. However, since this ribozyme was previously found to be inactive in vitro (8) , Rz 1-14 is not likely to cleave the completely spliced HIV-1 RNAs. The AS Psi-gag RNA is targeted against the HIV-1 Psi signal and the gag-coding region of the unspliced HIV-1 RNA. The binding of this RNA to the unspliced HIV-1 RNA occurs over 1553 nts and to the singly and completely spliced RNAs over 196 nts. Antisense RNAs over 800 nts in length were previously reported to inhibit HIV-1 replication better than their smaller counterparts (9, 11, 27) . Therefore, the AS Psi-gag RNA is expected to act primarily at the level of the unspliced RNA. In vitro cleavage activity of multimeric ribozymes amplified from the stable MT4 transductants. Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] and Rz 1-14 were RT-PCR amplified from the total RNA extracted from MGIN-Rz 1-9 and MGIN-Rz 1-14 -transduced cells to generate a T7 promotercontaining template DNA. This DNA was transcribed in vitro to obtain Rz 1-9 and Rz 1-14 , which were then used in a trans cleavage reaction with the alpha 32 P-labeled target RNA containing the HIV-1 env target sites. The alpha 32 P-labeled target RNA (lane 1) and its cleavage products (lanes 2,3) were analyzed by 8-M urea-6% polyacrylamide gel electrophoresis, followed by autoradiography. An arrow indicates the band corresponding to the uncleaved target RNA. Amphotropic vector particles were used to transduce the human CD4+ T lymphoid MT4 cell line. The uninfected stable transductants were shown to contain the genes encoding the multimeric ribozymes and/or the antisense RNA (Figure 3 ), and to allow similar level of expression of all interfering RNAs (Figure 4) . The multimeric ribozymes expressed in these cells were also shown to be active in vitro ( Figure 5 ). Cells expressing the multimeric ribozymes and/or the antisense RNA were viable and showed no sign of toxicity (results not shown).
Stable MT4 transductants expressing various interfering RNAs were then challenged with HIV-1. Cells transduced with the control MGIN vector produced high amount of HIV-1. Significant inhibition of HIV-1 replication was observed in MT4 cells expressing Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] or Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Little inhibition of HIV-1 replication was observed in the cells expressing the AS Psi-gag RNA. In MT4 cells expressing the Rz 1-9 AS Psi-gag or Rz 1-14 AS Psi-gag , virus replication was inhibited, but to a lesser degree than in the cells expressing the multimeric ribozymes alone ( Figure 6 ).
These results indicate that the Rz 1-9 and Rz 1-14 inhibit HIV-1 replication better than the AS Psi-gag RNA. And, that the AS Psi-gag RNA co-expression with Rz 1-9 or Rz 1-14 decreases the antiviral potential of these ribozymes.
The multimeric hammerhead ribozymes and the antisense RNA are targeted against different regions of HIV-1 RNA. Therefore, although Rz 1-9 and AS Psi-gag within the Rz 1-9 AS Psi-gag RNA or Rz 1-14 and AS Psi-gag within the Rz 1-14 AS Psi-gag RNA might both interact with the same unspliced HIV-1 RNA, they are designed not to compete with each other for binding to a common HIV-1 target site. Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] and AS Psi-gag or Rz 1-14 and AS Psi-gag are also not expected to interact with each other.
Similar length antisense RNAs (11, 27) and Rz 1-9 (7) were previously shown to inhibit the accumulation of HIV-1 RNA. Target site location within the HIV-1 RNA is not critical if the antisense RNA and the multimeric ribozymes act pre-splicing, since then the singly and completely spliced HIV-1 RNAs will not be generated. However, a post-splicing activity would be required for the spliced HIV-1 RNAs that escape degradation or cleavage by the antisense RNA or ribozymes. Although the AS Psi-gag RNA, Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] , and Rz 1-14 all act at the level of unspliced HIV-1 RNA, the Rz 1-9 and Rz 1-14 have the added advantage of also acting at the level of singly spliced HIV-1 RNAs. This may be one of the reasons why these multimeric ribozymes inhibit better than the antisense RNA.
The AS Psi-gag would mainly target the unspliced HIV-1 RNA. Therefore, it would prevent the co-expressed Rz 1-9 and Rz 1-14 from acting at the level of unspliced (and not the singly spliced) HIV-1 RNA.
The antisense-HIV RNA hybrids are subject to RNase degradation. Therefore, the antisense RNA is consumed in the reaction, whereas the ribozymes are notthey only cleave the target RNA, which is further degraded by the cell. As a result, compared to the HIV-1-infected MT4 cells that express the Rz 1-9 or Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , ribozyme levels will be lower in the HIV-1 infected cells that express the AS Psi-gag -Rz 1-9 or AS Psi-gag -Rz [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . This would further explain why the combination strategy was not better.
Our results indicate that the antisense RNA and ribozymes should not be co-expressed as a single transcription unit. Also, the multimeric ribozyme-based strategy seems to be better than the antisense RNA-based strategy. Therefore, the combination strategies must be carefully designed as the choice/design of the vector and the interfering RNAs present on a single or even a different transcript may interfere with each other's activity.
